Answers are grounded in this paper and cite their sources.
In silico analysis identifies EMB-3 as a promising candidate for skin scar regeneration, suggesting potential therapeutic applications.
Correction (new version, 2026-07-21) — citation correction. Correction (2026-07-21) - withdrawn-panel forward reference. A residual forward-looking item in Section 4.5 still promised a 'Boltz-2 calibration on the 15-compound ChEMBL MMP-1 inhibitor panel (in progress)'. That panel is the one withdrawn for fabricated annotations, so the promise is void; the item now states that any replacement calibration must be built from a recorded, scripted retrieval. This supplements the 2026-07-18 correction to this record. No result, ranking or figure value changes; this is a provenance and scope-of-claim correction. Full audit: preprints/_metadata/DANGLING_CITATION_AUDIT_2026_07_21.md; underlying finding: preprints/_metadata/FABRICATED_PANEL_SCOPE_2026_07_16.md. Correction (new version, 2026-07-18) — integrity correction. Corrected version (2026-07-18). This preprint contains no fabricated panel of its own; it had referenced a companion 15-compound MMP-1 calibration (in preprint #8) that has since been withdrawn because its panel carried fabricated potencies. Those two references are updated to state that the Boltz-2 affinity_probability_binary metric is used purely as a relative-ranking signal (consistent with the model's reported held-out Spearman of about 0.55–0.65); no other content changes. In silico only. HanCheongWoo ¹,²,³ ORCID: [0009-0004-4805-8815](https://orcid.org/0009-0004-4805-8815)
No takes yet. Share an insight, caveat, or question.
Cheongwoo Han (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: